Current Report Filing (8-k)
May 29 2020 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 28, 2020
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37852
|
|
98-0505495
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices,
including zip code)
(510) 474-0170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.00001
|
|
PTGX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item
5.07. Submission of Matters to a Vote of Security Holders
At the Protagonist Therapeutics,
Inc. (the “Company”) 2020 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 28, 2020, the
stockholders voted on the two proposals listed below. The proposals are described in detail in the Company’s definitive proxy
statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 16, 2020. The results of the matters
voted upon at the meeting were:
Proposal
1 — To elect the two Class I directors named below to serve until the 2023 Annual Meeting of Stockholders. Each
of the two named nominees was so elected, with the votes thereon at the Annual Meeting as follows:
|
|
Final Voting Results
|
|
Nominees
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Dinesh V. Patel, Ph.D.
|
|
|
16,515,423
|
|
|
|
1,916,749
|
|
|
|
3,542,396
|
|
Sarah Noonberg, M.D., Ph.D.
|
|
|
16,397,931
|
|
|
|
2,034,241
|
|
|
|
3,542,396
|
|
Proposal
2 — To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young
LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. This proposal
was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:
Final Voting Results
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Votes
|
|
|
21,966,944
|
|
|
|
3,185
|
|
|
|
4,439
|
|
|
|
—
|
|
No other matters were submitted
for stockholder action.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protagonist Therapeutics,
Inc.
|
Dated: May 29, 2020
|
|
|
By:
|
/s/ Don Kalkofen
|
|
|
Don Kalkofen
|
|
|
Chief Financial Officer
|
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Apr 2023 to Apr 2024